Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rusfertide (PTG-300) in Polycythemia Vera (PACIFIC)
NCT04767802Phase 2Completed
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Feb 2021
- Primary completion
- Mar 2023
- Modality
- Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of rusfertide in polycythemia vera (PV), sponsored by Protagonist Therapeutics, Inc.. Started Feb 2021; status: completed.
02
Drugs
rusfertide
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT04767802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04767802.